Johnson & Johnson (JNJ)

All Comments on JNJ

  • commenter
    TopForeignSt
    ocks
    Oct 05 02:00 PM
    My Website
    36 Opportunities for the Beginning of the Bull [view article]
    Interesting picks.Agree RY and HBC are two strong financials in these times. Reply
  • commenter
    cashew
    Oct 03 09:05 PM
    Hide in the Fetal Position - Fast Money Recap (10/2/08) [view article]
    Macke is right cash is it !!!!!!!!!!! Reply
  • commenter
    cashew
    Oct 03 09:04 PM
    Hide in the Fetal Position - Fast Money Recap (10/2/08) [view article]
    macke is right cash is it !!!!!!!!! Reply
  • commenter
    ajhough
    Oct 03 02:36 PM
    Dividend Aristocrats Survived September [view article]
    I own a good number of stocks in the list and have held my own quite well during September. However, the economy must be allowed to grow. Reply
  • commenter
    User 274213
    Oct 03 02:10 PM
    Nuclear Winter Pick - Cramer's Mad Money (9/24/08) [view article]
    no money in the ATM? did they run out of paper to print money on? Reply
  • commenter
    User 274213
    Oct 03 02:09 PM
    Nuclear Winter Pick - Cramer's Mad Money (9/24/08) [view article]
    why should we believe anything any of those people say? Reply
  • commenter
    Norman
    Lepoff, M.D.
    Oct 03 10:39 AM
    Hide in the Fetal Position - Fast Money Recap (10/2/08) [view article]
    These flakes are almost as bad as Cramer. Reply
  • commenter
    Ohad Hammer
    Oct 03 09:17 AM
    My Website
    Licensing Deal Is Imminent for ArQule [view article]
    Thanks Basel Expat.

    EXEL looks great at the current price. Similar to the overall market, all bad news (cash burn) are factored in and when multiple licensing deals are signed, I see it going substantially higher. It is less risky than ARQL, no doubt, thanks to its broad portfolio, and this should be ARQL's model as well.

    EXEL just got involved in another crowded "next big thing" area yesterday, Hsp90 inhibitors. In this case it is lagging behind BMS
    and SNTA among others.

    Ohad

    Reply
  • commenter
    Basel Expat
    Oct 03 08:41 AM
    Licensing Deal Is Imminent for ArQule [view article]
    Great article on the "next big thing" in oncology and why I am long on EXEL. Reply
  • commenter
    Tom B
    Oct 03 08:27 AM
    Licensing Deal Is Imminent for ArQule [view article]
    "Junk" is a good word for Aria.

    See: pipeline.corante.com/a...     Reply
  • commenter
    Ohad Hammer
    Oct 03 02:19 AM
    My Website
    Licensing Deal Is Imminent for ArQule [view article]
    Thanks

    I Don't follow ARIA too closely.     Reply
  • commenter
    Curbs-In
    Oct 02 11:19 PM
    Hide in the Fetal Position - Fast Money Recap (10/2/08) [view article]
    Cramer and CNBC = Afterbirth Reply
  • commenter
    cposch2004
    Oct 02 04:48 PM
    Licensing Deal Is Imminent for ArQule [view article]
    This is a good analysis. I'm curious, do you follow that junk ARIA and what are your thoughts there? Thanks Reply
  • commenter
    nelsb@centur
    ytel.net
    Oct 02 12:07 PM
    Johnson & Johnson: A Defensive, Less Volatile Investment Option [view article]
    I thank God for the good fortune of owning J & J since the Tylenol scare. It is the cornerstone of my portfolio. Reply
  • commenter
    nelsb@centur
    ytel.net
    Oct 02 12:05 PM
    Johnson & Johnson: A Defensive, Less Volatile Investment Option [view article]
    Thank God I have owned J & J since the Tylenol scare. It is the cornerstone of my portfolios and has done really well for me. Reply
Loading...
Symbols:
Authors:
Quick Links: